Clinical trials have long relied on traditional control arms—groups of participants receiving a placebo or standard-of-care treatment—to prove the safety and efficacy of investigational therapies. However, with advances in real-world data (RWD) and analytics, synthetic control arms (SCAs) are emerging as a viable, patient-centered alternative. By using historical or external data instead of enrolling patients in a placebo or standard-of-care group, SCAs can accelerate timelines, reduce patient burden, and expand access to novel treatments. As we approach 2025, here’s how synthetic control arms are reshaping the clinical research landscape.

1. Understanding Synthetic Control Arms

Definition: A synthetic control arm is a constructed comparator group for a clinical trial, derived from previously collected patient data rather than new enrollments. This data can come from sources like:

  • Electronic Health Records (EHRs)

  • Historical clinical trial data

  • Patient registries

  • Real-world data (RWD), including claims databases and wearables

Rather than randomizing participants to receive a placebo or standard-of-care, trial sponsors use these existing datasets to “mimic” what would happen if a patient received the conventional treatment. This approach allows the investigational therapy to be tested in a single-arm trial, where all enrolled patients receive the novel intervention, while the outcomes are compared against the synthetic data set.

2. Advantages of Synthetic Control Arms

  1. Accelerated Recruitment and Reduced Attrition

  2. Ethical and Patient-Centric Approach

  3. Cost-Effectiveness and Resource Allocation

  4. Augmented Evidence Generation

3. Building a Valid Synthetic Control Arm

A well-designed synthetic control arm relies on rigorous data practices to ensure validity and regulatory acceptability. Key elements include:

  1. High-Quality Datasets

  2. Robust Matching Techniques

  3. Transparent Protocols and Validation

4. Regulatory Perspectives and Acceptance

Regulatory agencies like the FDA and EMA are increasingly open to leveraging real-world evidence (RWE) and novel trial designs—particularly when traditional trials are difficult or unethical. They have begun:

  • Publishing guidance documents on how to incorporate RWD in drug evaluations and how to ensure data integrity.

  • Encouraging pilot programs and initiatives (e.g., FDA’s Real-World Evidence Program) to explore how SCAs could streamline approval processes, especially in rare disease or oncology settings.

While enthusiasm for synthetic arms is growing, regulators maintain a high standard of evidence. Sponsors must demonstrate that these arms yield comparable (or superior) validity to traditional controls. Ensuring transparency in methodology and thorough documentation is essential for regulatory buy-in.

5. Integrating Genomic and Biomarker Data

One of the most transformative trends driving synthetic control arms is the use of genomic and biomarker data. By stratifying patients based on molecular profiles, sponsors can construct highly specific control cohorts that more accurately match the patient population of a given trial arm. This approach is especially relevant in:

  • Oncology: Where tumor mutational signatures guide targeted therapies.

  • Rare Diseases: Where even small genomic differences can significantly alter disease progression or treatment response.

These refined synthetic arms can reduce outcome variability and help pinpoint which subsets of patients are most likely to benefit from an experimental therapy.

6. Challenges and Potential Pitfalls

Despite the promise of SCAs, challenges remain:

  1. Data Quality and Completeness

  2. Biases in Historical Datasets

  3. Ethical and Privacy Considerations

  4. Regulatory Uncertainty

7. A Look Ahead

In the coming years, synthetic control arms are likely to be a mainstay in clinical trial design, particularly in:

  • Rare Disease Research: Where patient populations are too small or too vulnerable for traditional randomized controlled trials.

  • Precision Medicine and Oncology: Where advanced biomarkers and genomic data can identify near-identical patient cohorts for robust comparisons.

  • Pandemic or Crisis Situations: Where rapidly generated RWE can expedite the evaluation of life-saving interventions.

Technological advances—such as more sophisticated data harmonization platforms and AI-driven analytics—will continue to enhance the reliability and regulatory acceptance of SCAs. Moreover, ongoing collaborations among sponsors, CROs, patient advocacy groups, and regulatory bodies will shape best practices and standards, gradually normalizing the use of synthetic arms across multiple therapeutic areas.

Conclusion

Synthetic control arms represent a paradigm shift in how clinical trials are conducted, offering a patient-centered, efficient, and often more ethical alternative to traditional control groups. By intelligently leveraging high-quality historical and real-world data, sponsors can expedite trial timelines, lower costs, and increase patient participation—particularly in urgent or rare disease scenarios.

However, the journey to widespread adoption involves careful attention to data quality, matching methods, and regulatory rigor. As these obstacles are addressed and as the industry becomes more comfortable with innovative trial designs, synthetic control arms are set to become a powerful tool—one that redefines how we generate evidence and bring new therapies to patients who need them most.

Share Your Thoughts:

  • Have you encountered synthetic control arms in any of your research projects?

  • What do you see as the biggest challenge or opportunity for SCAs in your therapeutic area?

Join the conversation in the comments and let’s continue shaping a future of more effective, inclusive, and data-driven clinical trials.